Total Payments
$184,021
2024 Payments
$14,784
Companies
84
Transactions
1,074
Medicare Patients
13,371
Medicare Billing
$3.9M
Payment Breakdown by Category
Other$129,638 (70.4%)
Food & Beverage$20,151 (11.0%)
Travel$20,032 (10.9%)
Consulting$13,345 (7.3%)
Education$856.10 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $129,638 | 52 | 70.4% |
| Food and Beverage | $20,151 | 956 | 11.0% |
| Travel and Lodging | $20,032 | 35 | 10.9% |
| Consulting Fee | $13,345 | 14 | 7.3% |
| Education | $856.10 | 17 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $40,327 | 94 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $38,676 | 97 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $26,265 | 21 | $0 (2018) |
| Celgene Corporation | $23,637 | 50 | $0 (2024) |
| GENZYME CORPORATION | $20,271 | 45 | $0 (2024) |
| Janssen Biotech, Inc. | $14,671 | 66 | $0 (2024) |
| Merck Sharp & Dohme LLC | $8,354 | 95 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,613 | 94 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $769.37 | 45 | $0 (2024) |
| Astellas Pharma US Inc | $692.64 | 30 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14,784 | 124 | GENZYME CORPORATION ($12,374) |
| 2023 | $9,699 | 123 | GENZYME CORPORATION ($7,317) |
| 2022 | $2,957 | 108 | Amgen Inc. ($792.91) |
| 2021 | $1,928 | 101 | Amgen Inc. ($244.17) |
| 2020 | $4,520 | 85 | Celgene Corporation ($2,292) |
| 2019 | $39,423 | 176 | E.R. Squibb & Sons, L.L.C. ($13,542) |
| 2018 | $59,288 | 198 | Amgen Inc. ($15,754) |
| 2017 | $51,423 | 159 | Janssen Scientific Affairs, LLC ($17,031) |
All Payment Transactions
1,074 individual payment records from CMS Open Payments — Page 1 of 43
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $14.62 | General |
| Category: HORMONE THERAPY | ||||||
| 12/19/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Somatuline Depot | Food and Beverage | In-kind items and services | $17.12 | General |
| Category: Oncology | ||||||
| 12/16/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $21.33 | General |
| Category: IMMUNOLOGY | ||||||
| 12/13/2024 | Geron Corporation | RYTELO (Drug) | Food and Beverage | In-kind items and services | $25.68 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/12/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $23.23 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Acrotech Biopharma Inc. | BELEODAQ (Drug) | Food and Beverage | In-kind items and services | $24.97 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $19.96 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $16.18 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $32.37 | General |
| Category: Oncology | ||||||
| 11/27/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $25.50 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/25/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $23.58 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $26.48 | General |
| Category: Oncology | ||||||
| 11/19/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,548.00 | General |
| Category: Oncology | ||||||
| 11/19/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Travel and Lodging | In-kind items and services | $972.36 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $13.94 | General |
| Category: Genetic Disease | ||||||
| 11/15/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $27.79 | General |
| 11/15/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $13.28 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $26.25 | General |
| Category: Oncology | ||||||
| 10/25/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $13.64 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/23/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $20.93 | General |
| 10/18/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $17.77 | General |
| 10/17/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: Oncology | ||||||
| 10/17/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $18.30 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/15/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $13.54 | General |
| Category: HORMONE THERAPY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 534 | 1,333 | $387,354 | $121,999 |
| 2022 | 67 | 4,325 | 92,667 | $4.1M | $1.4M |
| 2021 | 75 | 4,341 | 141,510 | $3.5M | $1.2M |
| 2020 | 74 | 4,171 | 120,216 | $3.4M | $1.2M |
Total Patients
13,371
Total Services
355,726
Medicare Billing
$3.9M
Procedure Codes
231
All Medicare Procedures & Services
231 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 27 | 254 | $57,658 | $22,888 | 39.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 23 | 201 | $73,164 | $21,517 | 29.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 150 | 229 | $56,563 | $18,187 | 32.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 63 | 112 | $50,176 | $14,711 | 29.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 58 | 166 | $26,560 | $9,942 | 37.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 56 | 77 | $28,028 | $9,577 | 34.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 54 | 54 | $27,810 | $8,605 | 30.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 19 | 106 | $26,182 | $7,482 | 28.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 22 | 49 | $13,230 | $4,234 | 32.0% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2023 | 26 | 39 | $19,812 | $2,204 | 11.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 22 | 27 | $4,428 | $1,495 | 33.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 14 | 19 | $3,743 | $1,157 | 30.9% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2022 | 12 | 11,280 | $620,400 | $245,385 | 39.6% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2022 | 11 | 5,400 | $540,000 | $228,015 | 42.2% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2022 | 20 | 5,720 | $715,000 | $188,979 | 26.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 37 | 6,420 | $183,480 | $108,561 | 59.2% |
| Q5115 | Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | Office | 2022 | 11 | 2,540 | $508,000 | $107,257 | 21.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 355 | 1,145 | $208,209 | $101,187 | 48.6% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2022 | 41 | 4,700 | $282,000 | $89,009 | 31.6% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2022 | 30 | 16,165 | $193,980 | $40,483 | 20.9% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 53 | 200 | $32,000 | $31,829 | 99.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 86 | 266 | $92,036 | $26,016 | 28.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 98 | 192 | $50,528 | $24,491 | 48.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 411 | 1,626 | $65,040 | $16,913 | 26.0% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2022 | 76 | 85 | $55,250 | $13,655 | 24.7% |
About Dr. George Geils, M.D
Dr. George Geils, M.D is a Hematology & Oncology healthcare provider based in Charleston, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1093773657.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. George Geils, M.D has received a total of $184,021 in payments from pharmaceutical and medical device companies, with $14,784 received in 2024. These payments were reported across 1,074 transactions from 84 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($129,638).
As a Medicare-enrolled provider, Geils has provided services to 13,371 Medicare beneficiaries, totaling 355,726 services with total Medicare billing of $3.9M. Data is available for 4 years (2020–2023), covering 231 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Charleston, SC
- Active Since 05/03/2006
- Last Updated 10/02/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1093773657
Products in Payments
- DARZALEX (Biological) $40,359
- EMPLICITI (Biological) $37,370
- Kyprolis (Biological) $25,653
- Revlimid (Drug) $20,851
- SARCLISA (Biological) $19,671
- XGEVA (Biological) $8,848
- KEYTRUDA (Biological) $8,203
- Nplate (Biological) $3,275
- Kyprolis (Drug) $1,471
- OPDIVO (Biological) $905.93
- ELIQUIS (Drug) $403.53
- VERZENIO (Drug) $282.85
- AFINITOR (Drug) $271.08
- TAGRISSO (Drug) $256.54
- CYRAMZA (Drug) $256.48
- JEVTANA (Drug) $255.67
- Blincyto (Biological) $230.50
- CALQUENCE (Drug) $227.84
- ELITEK (Biological) $227.64
- INJECTAFER (Drug) $221.89
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Charleston
Mr. David Ellison, M.d, M.D
Hematology & Oncology — Payments: $39,035
Hematology & Oncology $39,035
Dr. Albert Lockhart, Md, MD
Hematology & Oncology — Payments: $36,997
Hematology & Oncology $36,997
Dr. Irl Greenwell, M.d, M.D
Hematology & Oncology — Payments: $30,803
Hematology & Oncology $30,803
Dr. Brian Lingerfelt, Md, MD
Hematology & Oncology — Payments: $30,721
Hematology & Oncology $30,721
Robert Stuart, Md, MD
Hematology & Oncology — Payments: $25,933
Hematology & Oncology $25,933
Dr. George Keogh, M.d, M.D
Hematology & Oncology — Payments: $18,248
Hematology & Oncology $18,248